Equity Overview
Price & Market Data
Price: $3.78
Daily Change: $0.00 / 0.00%
Daily Range: $3.36 - $3.94
Market Cap: $31,526,016
Daily Volume: 37,536
Performance Metrics
1 Week: 5.29%
1 Month: 21.54%
3 Months: -20.75%
6 Months: -14.86%
1 Year: 123.7%
YTD: -20.75%
Company Details
Employees: 46
Sector: Health technology
Industry: Biotechnology
Country: Denmark
Details
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1, a multi-component prophylactic vaccine targeting skin and soft tissue infections with S. aureus bacteria; EVX-B2 to target multi-component prophylactic vaccine against gonorrhea bacteria; EVX-B3 to target bacterial pathogen associated with repeated infections; and EVX-V1, a multi-component prophylactic vaccine candidate for cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.